Results of Phase II “CHOICE” Study Published
March 10th, 2010 | 
Author: Results of Phase II "CHOICE" Study Published, Showing that Daclizumab Reduced Disease Activity in Relapsing MS, and Revealing Novel Immune Mechanism
230 people with relapsing MS taking interferon beta and having disease activity were administered one of two doses of daclizumab (Biogen Idec and Facet Biotech Corp.) or placebo - show that the higher dose reduced disease activity on MRI scans by 72% and the lower dose by 25%. Immune analyses show that this reduction was associated with a dramatic increase in CD56bright NK cells - an unexpected finding. Daclizumab is a laboratory-created monoclonal antibody that blocks the activity of interleukin-2 receptor-alpha, a key immune activator in MS. The drug is approved for use in organ transplant rejection. The Lancet Neurology, Early Online Publication, 16 February 2010
Posted in News | 
Tags: course of multiple sclerosis, multiple sclerosis bladder, multiple sclerosis central nervous system, multiple sclerosis cure, multiple sclerosis diagnosis, multiple sclerosis early treatment, multiple sclerosis fatigue, multiple sclerosis health, multiple sclerosis immune system, multiple sclerosis management, multiple sclerosis relapse, multiple sclerosis symptoms, multiple sclerosis therapy, multiple sclerosis tingling